1. Home
  2. RPRX vs EMA Comparison

RPRX vs EMA Comparison

Compare RPRX & EMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPRX
  • EMA
  • Stock Information
  • Founded
  • RPRX 1996
  • EMA 1998
  • Country
  • RPRX United States
  • EMA Canada
  • Employees
  • RPRX N/A
  • EMA N/A
  • Industry
  • RPRX Biotechnology: Pharmaceutical Preparations
  • EMA Electric Utilities: Central
  • Sector
  • RPRX Health Care
  • EMA Utilities
  • Exchange
  • RPRX Nasdaq
  • EMA Nasdaq
  • Market Cap
  • RPRX 13.9B
  • EMA 13.6B
  • IPO Year
  • RPRX 2020
  • EMA N/A
  • Fundamental
  • Price
  • RPRX $35.59
  • EMA $45.66
  • Analyst Decision
  • RPRX Strong Buy
  • EMA
  • Analyst Count
  • RPRX 3
  • EMA 0
  • Target Price
  • RPRX $48.33
  • EMA N/A
  • AVG Volume (30 Days)
  • RPRX 3.5M
  • EMA 162.4K
  • Earning Date
  • RPRX 08-06-2025
  • EMA 08-08-2025
  • Dividend Yield
  • RPRX 2.48%
  • EMA 4.54%
  • EPS Growth
  • RPRX 37.60
  • EMA 32.03
  • EPS
  • RPRX 2.45
  • EMA 2.07
  • Revenue
  • RPRX $2,263,845,000.00
  • EMA $5,467,005,251.00
  • Revenue This Year
  • RPRX $29.35
  • EMA $16.03
  • Revenue Next Year
  • RPRX $7.58
  • EMA N/A
  • P/E Ratio
  • RPRX $14.47
  • EMA $22.21
  • Revenue Growth
  • RPRX 1.13
  • EMA 9.93
  • 52 Week Low
  • RPRX $24.05
  • EMA $43.90
  • 52 Week High
  • RPRX $36.89
  • EMA $46.45
  • Technical
  • Relative Strength Index (RSI)
  • RPRX 52.61
  • EMA N/A
  • Support Level
  • RPRX $35.24
  • EMA N/A
  • Resistance Level
  • RPRX $36.89
  • EMA N/A
  • Average True Range (ATR)
  • RPRX 0.62
  • EMA 0.00
  • MACD
  • RPRX -0.14
  • EMA 0.00
  • Stochastic Oscillator
  • RPRX 22.16
  • EMA 0.00

About RPRX Royalty Pharma plc

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

About EMA Emera Incorporated Common Shares

Emera is a geographically diverse energy and services company investing in electricity generation, transmission, and distribution as well as gas transmission and utility energy services. Emera has operations throughout North America and the Caribbean countries.

Share on Social Networks: